News

Seeking Alpha6d
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
"Our study confirms that DecisionDx-Melanoma achieves this by providing significant risk stratification, outperforming the standard of care (i.e., AJCC staging) and the CP-GEP genomic test.” ...
Yahoo Finance11d
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
this study demonstrates that DecisionDx-Melanoma can identify early-stage CM patients (American Joint Committee on Cancer (AJCC) stage I-II, n=1,661) at higher risk of distant metastasis (DM ...